Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Takaaki Izumi"'
Autor:
Shunichi Hosoda, Goki Suda, Takuya Sho, Koji Ogawa, Megumi Kimura, Zijian Yang, Sonoe Yoshida, Akinori Kubo, Yoshimasa Tokuchi, Takashi Kitagataya, Osamu Maehara, Shunsuke Ohnishi, Akihisa Nakamura, Ren Yamada, Masatsugu Ohara, Naoki Kawagishi, Mitsuteru Natsuizaka, Masato Nakai, Kenichi Morikawa, Ken Furuya, Masaru Baba, Yoshiya Yamamoto, Kazuharu Suzuki, Takaaki Izumi, Takashi Meguro, Katsumi Terashita, Jun Ito, Takuto Miyagishima, Naoya Sakamoto
Publikováno v:
Liver Cancer (2022)
Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevac
Externí odkaz:
https://doaj.org/article/479658ebbf534b088e03eafa8651074d
Autor:
Shunichi Hosoda, Goki Suda, Takuya Sho, Koji Ogawa, Megumi Kimura, Zijian Yang, Sonoe Yoshida, Akinori Kubo, Yoshimasa Tokuchi, Takashi Kitagataya, Osamu Maehara, Shunsuke Ohnishi, Akihisa Nakamura, Ren Yamada, Masatsugu Ohara, Naoki Kawagishi, Mitsuteru Natsuizaka, Masato Nakai, Kenichi Morikawa, Ken Furuya, Masaru Baba, Yoshiya Yamamoto, Kazuharu Suzuki, Takaaki Izumi, Takashi Meguro, Katsumi Terashita, Jun Ito, Takuto Miyagishima, Naoya Sakamoto
Publikováno v:
Liver Cancer. 12(2):156-170
Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fe6423514a7c3595b1649528538a86f
http://hdl.handle.net/2115/89785
http://hdl.handle.net/2115/89785
Autor:
Masatsugu Ohara, Koji Ogawa, Goki Suda, Megumi Kimura, Osamu Maehara, Tomoe Shimazaki, Kazuharu Suzuki, Akihisa Nakamura, Machiko Umemura, Takaaki Izumi, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Shunsuke Ohnishi, Naoya Sakamoto
Publikováno v:
Hepatology Communications, Vol 2, Iss 8, Pp 910-922 (2018)
Liver cirrhosis (LC) is a major cause of secondary sarcopenia. Sarcopenia makes the prognosis worse; thus, novel therapeutic options for sarcopenia in patients with LC are urgently required as they are currently limited. In this retrospective study,
Externí odkaz:
https://doaj.org/article/1910db790a9744fbba7e24df81fb4632
Autor:
Goki Suda, Masaru Baba, Yoshiya Yamamoto, Takuya Sho, Koji Ogawa, Megumi Kimura, Shunichi Hosoda, Sonoe Yoshida, Akinori Kubo, Qingjie Fu, Zijian Yang, Yoshimasa Tokuchi, Takashi Kitagataya, Osamu Maehara, Shunsuke Ohnishi, Ren Yamada, Masatsugu Ohara, Naoki Kawagishi, Mitsuteru Natsuizaka, Masato Nakai, Kenichi Morikawa, Ken Furuya, Kazuharu Suzuki, Takaaki Izumi, Takashi Meguro, Katsumi Terashita, Jun Ito, Tomoe Kobayashi, Izumi Tsunematsu, Naoya Sakamoto
Publikováno v:
Journal of Medical Virology. 95
No prospective study on the efficacy of tenofovir alafenamide (TAF), a novel tenofovir prodrug, in preventing HBV reactivation has yet been reported.This multicenter prospective study enrolled HBV-carriers who received TAF to prevent HBV reactivation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a03211a559e165ccd84e1282a4307049
https://doi.org/10.1002/jmv.28452
https://doi.org/10.1002/jmv.28452
Autor:
Naoki Kawagishi, Goki Suda, Akinobu Nakamura, Megumi Kimura, Osamu Maehara, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Takaaki Izumi, Machiko Umemura, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Yusuke Kudo, Mutsumi Nishida, Hideaki Miyoshi, Naoya Sakamoto
Publikováno v:
PLoS ONE, Vol 13, Iss 12, p e0209615 (2018)
AIM:We comprehensively analyzed how hepatitis C virus (HCV) eradication by interferon (IFN)-free direct-acting-antiviral-agents (DAAs) affects liver steatosis and atherogenic risk. METHODS:Patients treated with IFN-free-DAAs who underwent transient e
Externí odkaz:
https://doaj.org/article/183f198e79584153bc811e194129dbbf
Autor:
Takuya Sho, Goki Suda, Yoshiya Yamamoto, Ken Furuya, Masaru Baba, Koji Ogawa, Akinori Kubo, Yoshimasa Tokuchi, Qingjie Fu, Zijian Yang, Megumi Kimura, Takashi Kitagataya, Osamu Maehara, Shunsuke Ohnishi, Akihisa Nakamura, Ren Yamada, Masatsugu Ohara, Naoki Kawagishi, Mitsuteru Natsuizaka, Masato Nakai, Kazuharu Suzuki, Takaaki Izumi, Takashi Meguro, Katsumi Terashita, Tomofumi Takagi, Jun Ito, Tomoe Kobayashi, Takuto Miyagishima, Naoya Sakamoto
Publikováno v:
Cancers; Volume 14; Issue 16; Pages: 3938
Simple Summary The IMbrave150 trial led to the approval of atezolizumab and bevacizumab for the treatment of unresectable hepatocellular carcinoma (HCC). We performed a retrospective multicenter study including 115 patients with unresectable HCC trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96b9fda5306a7c84704762d79fef1c65
Autor:
Machiko Umemura, Koji Ogawa, Kenichi Morikawa, Akinori Kubo, Yoshimasa Tokuchi, Ren Yamada, Takashi Kitagataya, Taku Shigesawa, Tomoe Shimazaki, Megumi Kimura, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Naoki Kawagishi, Takaaki Izumi, Masato Nakai, Takuya Sho, Goki Suda, Mitsuteru Natsuizaka, Kota Ono, Kazumoto Murata, Masaya Sugiyama, Masashi Mizokami, Naoya Sakamoto
Publikováno v:
Hepatology research : the official journal of the Japan Society of HepatologyREFERENCES. 52(7)
Benefits of nucleos(t)ide analogs (NAs) on hepatitis B surface antigen (HBsAg) reduction and interferon-lambda3 (IFN-λ3) induction are still not known. This study aimed to investigate the effects of NAs on HBsAg reduction and association with serum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a114e938abd5d5b5878ac432cefc596
https://pubmed.ncbi.nlm.nih.gov/35352445
https://pubmed.ncbi.nlm.nih.gov/35352445
Autor:
Akihisa Nakamura, Koji Yamamoto, Rei Takeda, Ren Yamada, Akinori Kubo, Kenichi Morikawa, Sayaka Ando, Tomoe Shimazaki, Takaaki Izumi, Machiko Umemura, Takashi Kitagataya, Taku Shigesawa, Kazuharu Suzuki, Megumi Kimura, Masato Nakai, Takuya Sho, Goki Suda, Mitsuteru Natsuizaka, Koji Ogawa, Shunsuke Ohnishi, Toshiro Sugiyama, Hiroshi Takeda, Naoya Sakamoto
Publikováno v:
Hepatology research : the official journal of the Japan Society of HepatologyREFERENCES. 52(6)
Although various noninvasive markers and prediction formulas for nonalcoholic steatohepatitis (NASH) have been reported, they are of value only in the diagnosis of the advanced fibrosis stage of NASH. In this study, we evaluated soluble CD14 (sCD14)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07265f0e93f0cf82424e913e80cff943
https://pubmed.ncbi.nlm.nih.gov/35129841
https://pubmed.ncbi.nlm.nih.gov/35129841
Autor:
Takuya Sho, Ken Furuya, Masaru Baba, Masatsugu Ohara, Kazuharu Suzuki, Osamu Maehara, Taku Shigesawa, Jun Ito, Shunsuke Ohnishi, Yoshimasa Tokuchi, Katsumi Terashita, Koji Ogawa, Naoki Kawagishi, Takaaki Izumi, Takashi Kitagataya, Megumi Kimura, Akinori Kubo, Masato Nakai, Takashi Meguro, Kenichi Morikawa, Akihisa Nakamura, Takuto Miyagishima, Mitsuteru Natsuizaka, Naoya Sakamoto, Goki Suda, Yoshiya Yamamoto, Ren Yamada
Publikováno v:
Hepatology research : the official journal of the Japan Society of HepatologyREFERENCES. 51(9)
AIM A clinical trial (IMbrave150) indicated the efficacy and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma (HCC). In this study, we evaluated this therapeutic combination in a real-world setting, with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a4bd6f1334755d87e2145f4d036344d
https://pubmed.ncbi.nlm.nih.gov/34245216
https://pubmed.ncbi.nlm.nih.gov/34245216
Autor:
Yoshihito Uchida, Yoshiya Yamamoto, Masatsugu Ohara, Yoshiyuki Ueno, Katsumi Terasita, Chitomi Hasebe, Naoya Sakamoto, Koji Ogawa, Naoki Kawagishi, Jun Inoue, Yoko Tsukuda, Masaru Baba, Tomoe Kobayashi, Kazumichi Abe, Hiromasa Ohira, Hiroaki Haga, Mitsuteru Natsuizaka, Ken Furuya, Satoshi Mochida, Jun Itakura, Masayuki Kurosaki, Atsushi Takahashi, Kenichi Morikawa, Goki Suda, Masami Abe, Masato Nakai, Takuya Sho, Namiki Izumi, Takaaki Izumi
Publikováno v:
Journal of Gastroenterology. 54:641-649
Until recently, interferon-free anti-hepatitis C virus (HCV) therapy for genotype 2 (GT2) HCV-infected hemodialysis patients was an unfulfilled medical need. Recent clinical trials of glecaprevir and pibrentasvir (G/P) for hemodialysis patients showe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca1b43ddd84ec09ea89f0e04a8153f06
https://doi.org/10.1007/s00535-019-01556-y
https://doi.org/10.1007/s00535-019-01556-y